Genesystem Co., Ltd. (KOSDAQ:363250)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,325.00
+30.00 (0.70%)
At close: Dec 5, 2025
-55.13%
Market Cap 29.50B
Revenue (ttm) 345.38M
Net Income (ttm) -8.94B
Shares Out 6.82M
EPS (ttm) -1,313.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 76,968
Average Volume 80,929
Open 4,350.00
Previous Close 4,295.00
Day's Range 4,100.00 - 4,350.00
52-Week Range 4,100.00 - 11,480.00
Beta 0.51
RSI 25.87
Earnings Date Nov 14, 2025

About Genesystem

Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterinary diagnostics; food safety assays comprising foodborne pathogen detection kits, HALAL food testing kits, and meat species identification kits; and nuc... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 2010
Employees 54
Stock Exchange KOSDAQ
Ticker Symbol 363250
Full Company Profile

Financial Performance

In 2024, Genesystem's revenue was 1.21 billion, an increase of 34.64% compared to the previous year's 897.03 million. Losses were -8.92 billion, 12.6% more than in 2023.

Financial Statements

News

There is no news available yet.